Membership Update — December 2012
BioNJ welcomes Kissei America, Inc., OrthogenRx, Inc., and RXi Pharmaceuticals Corp. as Core Members for 2012. Kissei America, Inc. Kissei America, Inc., is the U.S. subsidiary of Kissei Pharma, a medium-sized pharma company based in Japan. Kissei is actively seeking in-licensing, out-licensing, and other business development opportunities for new drugs. OrthogenRx, Inc. OrthogenRx, Inc., is [...]
Membership Update – September 2012
BioNJ welcomes Enzon Pharmaceuticals back to BioNJ as a Core Member for 2012. Enzon Pharmaceuticals, Inc. Enzon Pharmaceuticals, Inc., is a biotechnology company dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs. Enzon’s drug-development programs utilize two platforms — Customized PEGylation Linker Technology (Customized Linker Technology®) and third-generation [...]
Membership Update – July/August 2012
BioNJ welcomes Sheppard, Mullin, Richter & Hampton as a new Diamond Member for 2012. Sheppard, Mullin, Richter & Hampton LLP Sheppard Mullin is a leader in intellectual property law with exclusive expertise in litigation, transactions and patent strategy and counseling. We counsel a wide variety of clients in healthcare, biotech and pharmaceuticals, medical devices, regulatory, [...]
Membership Update – May 2012
BioNJ welcomes American Cryostem Corporation and Aptalis Pharmatech, Inc. as new Core Members for 2012. American Cryostem Corporation American CryoStem is a life sciences company, founded in 2008 and headquartered in Red Bank. The company has created and commercialized patented products and a proprietary platform to clinically process and cryopreserve adipose tissue, adipose derived stromal [...]
Membership Update – April 2012
BioNJ welcomes Aerie Pharmaceuticals, Inc., and Archimedes Pharma as new Core Members for 2012. Aerie Pharmaceuticals, Inc. Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. All technology of the company is based on internal discovery R&D and is protected by a strong IP [...]
Membership Update – March 2012
BioNJ Announces the Diamond Circle! BioNJ is proud to announce the formation of the Diamond Circle. Composed of our Leadership Members and Diamond Members, the Diamond Circle will provide a venue for direct interaction with the BioNJ Board of Trustees on issues affecting the industry, including educational forums that will coincide with regularly scheduled Board [...]
Membership Update – February 2012
BioNJ welcomes Savient Pharmaceuticals as a new Diamond Member. Savient Pharmaceuticals, Inc. Savient Pharmaceuticals, Inc., is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses [...]
Membership Update – January 2012
BioNJ welcomes BioMatters, Inc., and HDL Apomics as new Core Members for 2012. Biomatters, Inc. Biomatters, Inc., develops and markets Geneious Pro, a revolutionary bioinformatics software platform that is both ultra-powerful and easy to use. Scientists, researchers, and students are able to search, organize, and analyze genomic and protein information via a single desktop program [...]
Membership Update – December 2011
BioNJ welcomes The Medicines Company as a new Platinum Member for 2011. The Medicines Company The Medicines Company is a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. We have three marketed products: Angiomax® (bivalirudin), Cleviprex® (clevidipine) injectable emulsion, [...]
Membership Update – November 2011
BioNJ welcomes Scrip Intelligence as a new Diamond Member for 2011: Scrip Intelligence Scrip Intelligence is the leading source of news, data, and analysis for the global pharmaceutical and biotech industries. Every day, by tapping into our extensive intelligence network, we give our subscribers the power to revolutionize their commercial and strategic thinking. With a [...]
Membership Update – October 2011
BioNJ welcomes GCA Therapeutics, Ltd., and iBio, Inc., as new Core Members for 2011: GCA Therapeutics, Ltd. GCA Therapeutics, Ltd. (GCAT) is a US-based, specialty pharmaceutical company focusing on in-licensing, acquisition, and marketing of mid- through late-stage drug candidates and technologies from North America and the EU. GCAT applies its expertise and resources in pre-clinical, [...]
Membership Update – September 2011
BioNJ welcomes Leerink Swan as a new Diamond Member for 2011: Leerink Swann Founded in 1995, Leerink Swann is recognized as a leading healthcare investment bank to a broad range of institutional, life sciences, corporate, and high-net-worth clients that are positioned to shape the future of healthcare. Leerink Swann’s deep domain knowledge provides its clients [...]
Membership Update – July 2011
BioNJ welcomes our new Diamond Members for 2011: Campbell Alliance Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm’s clients include most of the world’s top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a [...]
